The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to researchers.
Cases of gonorrhoea are increasing around the world, with estimates suggesting more than 82 million instances each year. Particularly high rates are reported in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.
“The approval of fresh medications for gonorrhoea is an important and timely step in the reality of increasing worldwide cases, escalating drug resistance and the highly restricted available drugs currently available.”
Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance found that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.
One new antibiotic, marketed under the name a brand name, was authorized by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to major issues, including infertility. Researchers believe that focused deployment of this new drug will help slow the spread of drug resistance.
Gepotidacin, created by the drugmaker GSK, was also approved in the same week. This medication, which is also used to treat urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.
Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP collaborated with the drug firm Innoviva to develop it.
“This approval marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”
According to findings published in a prominent scientific publication, zoliflodacin cured more than 90% of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which involves a dual-drug approach. The study enrolled over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.
As part of the agreement of its unique model, GARDP has the ability to make available and distribute the drug in many low-income and middle-income countries.
Doctors directly involved have shared optimism. Having a one-pill regimen like this is described as a "critical tool" for managing the epidemic. This is deemed vital to lessen the impact of the disease for people and to prevent the spread of highly drug-resistant gonorrhoea globally.
